Sugi Predict

Sugi Predict / Compounds / SCHEMBL20705018

SCHEMBL20705018

SCHEMBL20705018

COc1ccc(CN2C3(C)CCCC2(C)CC(=O)C3)cc1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CMA1 P23946 1/20 0.47
▸ GSK3A P49840 2/20 0.45
▸ GSK3B P49841 2/20 0.45
▸ ALDH1A1 P00352 3/20 0.45
▸ MEN1 O00255 2/20 0.45
▸ KMT2A Q03164 2/20 0.45
▸ MAPT P10636 2/20 0.45
▸ GAA P10253 1/20 0.45
▸ CYP11B2 P19099 1/20 0.43
▸ BLM P54132 1/20 0.42
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ LMNA P02545 1/20 0.41
▸ SIGMAR1 Q99720 1/20 0.41
▸ KDM4E B2RXH2 2/20 0.41
▸ ALOX15 P16050 1/20 0.41
▸ PTGIR P43119 1/20 0.40
▸ HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25092478 1.00 CMA1 (0.47) CMA1GSK3AGSK3BALDH1A1MEN1
SCHEMBL20705177 0.82 TSHR (0.40) CMA1GSK3AGSK3BALDH1A1MEN1
SCHEMBL25092696 0.80 CMA1 (0.40) CMA1GSK3AGSK3BALDH1A1MEN1
SCHEMBL25092697 0.80 CMA1 (0.40) CMA1GSK3AGSK3BALDH1A1MEN1
SCHEMBL22205620 0.79 SIGMAR1 (0.40) CMA1ALDH1A1MEN1KMT2AMAPT
SCHEMBL22205618 0.79 SIGMAR1 (0.40) CMA1ALDH1A1MEN1KMT2AMAPT
SCHEMBL22205621 0.79 SIGMAR1 (0.40) CMA1ALDH1A1MEN1KMT2AMAPT
SCHEMBL22313881 0.79 LMNA (0.41) CMA1GSK3AGSK3BALDH1A1MEN1
SCHEMBL11813133 0.79 SIGMAR1 (0.47) CMA1GSK3AGSK3BALDH1A1MEN1
SCHEMBL22313519 0.77 KMT2A (0.34) ALDH1A1MEN1KMT2AMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12522597-B2 Methods and compositions for modulating splicing SKYHAWK THERAPEUTICS, INC. (US) 2026-01-13 — — US disclosed
CN-111194215-B Methods and compositions for modulating splicing 斯基霍克疗法公司 2024-03-01 — — CN disclosed
CN-111499615-B Methods and compositions for modulating splicing 斯基霍克疗法公司 2024-02-02 — — CN disclosed
US-11603531-B1 Methods and compositions for modulating splicing SKYHAWK THERAPEUTICS, INC. (US) 2023-03-14 — — US disclosed
US-20230054781-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-02-23 — — US disclosed
US-20230059865-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-02-23 — — US disclosed
US-20230059865-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-02-23 — — US disclosed
US-20230020922-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-01-19 — — US disclosed
US-20220403383-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2022-12-22 — — US disclosed
US-20220403383-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2022-12-22 — — US disclosed
WO-2020163647-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. (US) 2020-08-13 — — WO disclosed
CN-111499615-A Methods and compositions for modulating splicing 斯基霍克疗法公司 2020-08-07 — — CN disclosed
US-20200247799-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2020-08-06 — — US disclosed
US-20200247799-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2020-08-06 — — US disclosed
EP-3689863-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING Skyhawk Therapeutics, Inc. (US) 2020-08-05 — — EP disclosed
US-20200224199-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2020-07-16 — — US disclosed
US-20200224199-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2020-07-16 — — US disclosed
EP-3661509-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING Skyhawk Therapeutics, Inc. (US) 2020-06-10 — — EP disclosed
CN-111194215-A Methods and compositions for modulating splicing 斯基霍克疗法公司 2020-05-22 — — CN disclosed
WO-2019028440-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. (US) 2019-02-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11603531-B1 Methods and compositions for modulating splicing RBM17, SF3B1, SNRPA1 CMA1 4477/4885GSK3A 2802/4885GSK3B 2688/4885
US-20230020922-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SNRPA1 CMA1 4477/4885GSK3A 2802/4885GSK3B 2688/4885
US-20200247799-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SNRPA1 CMA1 4477/4885GSK3A 2802/4885GSK3B 2688/4885
US-20220403383-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SNRPA1 CMA1 4477/4885GSK3A 2802/4885GSK3B 2688/4885
US-20230054781-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SF3B5 CMA1 4472/4885GSK3A 2487/4885GSK3B 2334/4885
US-20230059865-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SNRPA1 CMA1 4477/4885GSK3A 2802/4885GSK3B 2688/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.